2024-10-19 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of health care products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** ABT has generated a cumulative return of 111.07% compared to the S&P 500's (VOO) cumulative return of 136.97%.
* **Relative Divergence:** ABT is currently lagging behind the S&P 500 by -25.9%. This represents a relative divergence of 15.91% based on historical data, indicating that ABT is performing relatively worse than the benchmark.

**2. Recent Price Movement:**

* **Closing Price:** $117.89
* **5-day Moving Average:** $117.03
* **20-day Moving Average:** $114.56
* **60-day Moving Average:** $112.68

**3. Technical Indicators:**

* **RSI:** 72.46, indicating ABT is currently in overbought territory.
* **PPO:** 0.3, suggesting a potential bullish momentum.
* **Delta_Previous_Relative_Divergence:** 2.77,  showing a short-term upward trend in relative divergence.
* **Expected Return:** 0.0%. This suggests that ABT is not expected to outperform the S&P 500 in the next 5 years.

**4. Recent Earnings and Outlook:**

* **Earnings:** 
    * ABT has shown consistent earnings growth in the past year, with the most recent earnings per share (EPS) of $0.74 exceeding analyst expectations of $0.72.
    * Revenue has also been steadily increasing, reaching $10.38 billion in the most recent quarter, indicating healthy growth.
* **Outlook:** Analysts are generally optimistic about ABT's future prospects.  The company's diversified product portfolio, strong brand recognition, and focus on innovation are expected to drive continued growth.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Despite its relatively lower performance compared to the S&P 500, ABT has a strong track record of delivering stable returns and dividends. The company's focus on essential healthcare products positions it favorably in a fluctuating economic environment.
* **Analyst Opinions:** Most analysts maintain a "Buy" or "Hold" rating on ABT, citing its solid financial performance and growth potential.  
* **Performance Highlights:** The company has recently received regulatory approval for new products and made strategic acquisitions to expand its market presence. These developments are expected to contribute to ABT's continued growth in the coming years.

**6. Comprehensive Analysis:**

* ABT has a strong track record of delivering stable returns and dividends but has been lagging behind the S&P 500 in recent times.
* The company's technical indicators suggest a potential short-term upward trend, although the RSI suggests it is in overbought territory.
* ABT's strong financial performance and growth potential, coupled with a diversified product portfolio and focus on innovation, are positive factors for long-term investors.
* However, the company's recent relative performance and the lack of expected outperformance compared to the S&P 500 should be carefully considered before making any investment decisions.

**7. Conclusion:**

While ABT offers a solid investment opportunity with consistent growth potential, investors should carefully consider its recent relative performance against the S&P 500, its potential future outperformance, and the current market sentiment before making an investment decision.  Further research and analysis are recommended before making a final decision. 
